Achievements, challenges and prospects for the development of broadly protective multivalent vaccines and therapeutic antibodies against hand, foot and mouth disease

Lyu, Ke; Chen, Rong

doi:10.1007/s11434-015-0847-3

Cited by 4 publications

(1 citation statement)

References 59 publications

(103 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Repetition of highly conserved epitopes on the NP surface can induce the production of broadly neutralizing antibodies (bNAbs). [ 160 ] The highly conserved HA stem region of the IAV has been displayed on ferritin‐based NPs to generate cross‐reactive bNAbs against divergent influenza strains. [ 161 ] Multiple copies of an antigenically conserved B‐cell epitope mimetic based on pneumococcal surface protein A (PspA) were displayed on VLPs.…”

Section: Contribution Of Nanotechnology To Vaccine Immunity In Vivomentioning

confidence: 99%

Advances of Nanotechnology Toward Vaccine Development Against Animal Infectious Diseases

Wang

Gao

Wang

et al. 2023

Adv Funct Materials

View full text Add to dashboard Cite

Vaccines are the most effective means of controlling infectious diseases. Increasingly epidemics have driven the development of vaccines for human use. However, insufficient attention has been paid to preventing animal epidemics. The spread of animal epidemics directly affects food and nutritional safety, the economy, and outbreaks of zoonotic diseases, which can eventually threaten human health. Reducing safety risks, saving production costs, adapting to mass vaccination, and improving immunogenicity are important that must be considered in animal vaccines. Nanotechnology in vaccine development provides unique advantages in meeting these challenges, both at in vitro preparation and in vivo immune response levels. In terms of in vitro vaccine formulation, nanoparticles offer the possibility to provide multiple antigen display sites, maintain antigen conformation, and improve vaccine stability, which facilitates the development of vaccines with enhanced immunogenicity and thermal stability. In terms of in vivo vaccine‐induced immunity, nanoparticles show superior immunostimulatory activity which facilitates multiple immune response processes, including antigen delivery, cellular uptake, antigen presentation, and lymphocyte activation, thus markedly augmenting vaccine‐mediated immune responses. Herein, the application of nanotechnology to vaccine development and the characteristics of animal vaccines are reviewed, aiming to provide general guidelines for the design of future vaccines against animal infectious diseases and promote harmonious coexistence of humans and animals.

show abstract

Section: Contribution Of Nanotechnology To Vaccine Immunity In Vivomentioning

confidence: 99%

Advances of Nanotechnology Toward Vaccine Development Against Animal Infectious Diseases

Wang

Gao

Wang

et al. 2023

Adv Funct Materials

View full text Add to dashboard Cite

show abstract

An inactivated enterovirus 71 vaccine is safe and immunogenic in healthy adults: A phase I, double blind, randomized, placebo-controlled, study of two dosages

Tambyah

Oon

Asli

et al. 2019

Vaccine

View full text Add to dashboard Cite

Recent development of enterovirus A vaccine candidates for the prevention of hand, foot, and mouth disease

Fang

Liu

2018

Expert Review of Vaccines

View full text Add to dashboard Cite

Hand, foot, and mouth disease (HFMD) is a childhood illness commonly caused by enterovirus A. Enterovirus A71 (EV-A71) and coxsackievirus A16 (CV-A16) are the most commonly identified viruses associated with HFMD. Recently, outbreaks caused by different enterovirus A including CV-A6 and CV-A10 are increasing. Being available now to protect against EV-A71 infection, inactivated EV-A71 vaccines cannot prevent coxsackievirus infections, thus limiting their general application in controlling HFMD. Multivalent HFMD vaccines are suggested to have broad cross-neutralizing responses against these emerging enteroviruses. Areas covered: We discuss the recent development of enterovirus A vaccines including the inactivated whole-virion vaccine and virus-like particle vaccine candidates and review the information of neutralization epitopes of these viruses. Expert commentary: Evaluation of the efficacy and safety of the coxsackievirus vaccine and the multivalent HFMD vaccine candidates in clinical trials is urgently required. Epitopic analysis showed that common immunodominant sites exist across these enteroviruses. However, variations of amino acid residues in these regions limit the induction of cross-neutralization antibodies, and therefore, a multivalent HFMD vaccine is required for broad protection against HFMD. With the inclusion of major circulating viruses in the development of multivalent HFMD vaccines, an increase in the success in HFMD control is anticipated.

show abstract

Achievements, challenges and prospects for the development of broadly protective multivalent vaccines and therapeutic antibodies against hand, foot and mouth disease

Cited by 4 publications

References 59 publications

Advances of Nanotechnology Toward Vaccine Development Against Animal Infectious Diseases

Advances of Nanotechnology Toward Vaccine Development Against Animal Infectious Diseases

An inactivated enterovirus 71 vaccine is safe and immunogenic in healthy adults: A phase I, double blind, randomized, placebo-controlled, study of two dosages

Recent development of enterovirus A vaccine candidates for the prevention of hand, foot, and mouth disease

Contact Info

Product

Resources

About